​

Biohaven Stock (NYSE:BHVN)

ForecastOwnershipFinancialsChart
Biohaven by TradingView

Previous Close

$18.56

52W Range

$15.79 - $55.70

50D Avg

$30.04

200D Avg

$39.10

Market Cap

$1.91B

Avg Vol (3M)

$1.16M

Beta

4.15

Div Yield

-

BHVN Company Profile

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

256

IPO Date

Sep 23, 2022

Website

BHVN Performance

BHVN Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-885.11M$-436.05M$-567.93M
Net Income$-846.42M$-408.17M$-570.28M
EBITDA$-885.11M$-429.14M$-462.80M
Basic EPS$-9.28$-5.73$-12.75
Diluted EPS$-9.28$-5.73$-12.75

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 21Feb 25, 22 | 8:30 AM
Q3 21Nov 09, 21 | 1:08 PM
Q2 21Aug 09, 21 | 8:30 AM

Peer Comparison

TickerCompany
RVMDRevolution Medicines, Inc.
CCCCC4 Therapeutics, Inc.
TERNTerns Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
APLSApellis Pharmaceuticals, Inc.
DAWNDay One Biopharmaceuticals, Inc.
NRIXNurix Therapeutics, Inc.
AGIOAgios Pharmaceuticals, Inc.
KYMRKymera Therapeutics, Inc.
XFORX4 Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
INBXInhibrx Biosciences, Inc.
INZYInozyme Pharma, Inc.
IMNMImmunome, Inc.